The US company has a Phase III-ready program in the disease, ALZ-801, an oral small molecule inhibitor of beta amyloid misfolding and the consequent formation of small neurotoxic aggregates, or oligomers.

Alzheon also has a discovery platform of small molecules for the treatment of neurodegenerative disorders.